These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 28649363)

  • 21. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.
    Thakore PI; D'Ippolito AM; Song L; Safi A; Shivakumar NK; Kabadi AM; Reddy TE; Crawford GE; Gersbach CA
    Nat Methods; 2015 Dec; 12(12):1143-9. PubMed ID: 26501517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies.
    Banda A; Impomeni O; Singh A; Baloch AR; Hu W; Jaijyan DK
    Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Modification of Epigenetic Marks Using CRISPR/dCas9-SunTag-Based Modular Epigenetic Toolkit.
    Song MK; Kim YS
    Methods Mol Biol; 2024; 2761():81-91. PubMed ID: 38427231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR-Cas-mediated transcriptional control and epi-mutagenesis.
    Gardiner J; Ghoshal B; Wang M; Jacobsen SE
    Plant Physiol; 2022 Mar; 188(4):1811-1824. PubMed ID: 35134247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced scale and scope of genome engineering and regulation using CRISPR/Cas in Saccharomyces cerevisiae.
    Deaner M; Alper HS
    FEMS Yeast Res; 2019 Nov; 19(7):. PubMed ID: 31665284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility.
    Goell JH; Hilton IB
    Trends Biotechnol; 2021 Jul; 39(7):678-691. PubMed ID: 33972106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of next-generation of the epigenetic drugs.
    Rittiner J; Cumaran M; Malhotra S; Kantor B
    Front Bioeng Biotechnol; 2022; 10():1035543. PubMed ID: 36324900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergent CRISPR-Cas-based technologies for engineering non-model bacteria.
    Volke DC; Orsi E; Nikel PI
    Curr Opin Microbiol; 2023 Oct; 75():102353. PubMed ID: 37413959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Research Trends in Stem Cells Using CRISPR/Cas-Based Genome Editing Methods.
    Yoon DE; Lee H; Kim K
    Int J Stem Cells; 2024 Feb; 17(1):1-14. PubMed ID: 37904281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research.
    Yang Y; Xu J; Ge S; Lai L
    Front Med (Lausanne); 2021; 8():649896. PubMed ID: 33748164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survey of clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR/Cas) systems in multiple sequenced strains of Klebsiella pneumoniae.
    Ostria-Hernández ML; Sánchez-Vallejo CJ; Ibarra JA; Castro-Escarpulli G
    BMC Res Notes; 2015 Aug; 8():332. PubMed ID: 26238567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the CRISPR-Cas system in cancer drug development: Mechanisms of action and therapy.
    Chandrasekaran AP; Karapurkar JK; Chung HY; Ramakrishna S
    Biotechnol J; 2022 Jul; 17(7):e2100468. PubMed ID: 35157790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR-Mediated Synergistic Epigenetic and Transcriptional Control.
    Dominguez AA; Chavez MG; Urke A; Gao Y; Wang L; Qi LS
    CRISPR J; 2022 Apr; 5(2):264-275. PubMed ID: 35271371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
    Li C; Brant E; Budak H; Zhang B
    J Zhejiang Univ Sci B; 2021 Apr; 22(4):253-284. PubMed ID: 33835761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenome editing for targeted DNA (de)methylation: a new perspective in modulating gene expression.
    Seem K; Kaur S; Kumar S; Mohapatra T
    Crit Rev Biochem Mol Biol; 2024; 59(1-2):69-98. PubMed ID: 38440883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Programmable CRISPR-Cas transcriptional activation in bacteria.
    Ho HI; Fang JR; Cheung J; Wang HH
    Mol Syst Biol; 2020 Jul; 16(7):e9427. PubMed ID: 32657546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR-Based Technologies: Impact of RNA-Targeting Systems.
    Terns MP
    Mol Cell; 2018 Nov; 72(3):404-412. PubMed ID: 30388409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applications of the CRISPR/Cas system beyond gene editing.
    Anton T; Karg E; Bultmann S
    Biol Methods Protoc; 2018; 3(1):bpy002. PubMed ID: 32161796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of Engineered DNA-Binding Molecules Such as TAL Proteins and the CRISPR/Cas System in Biology Research.
    Fujita T; Fujii H
    Int J Mol Sci; 2015 Sep; 16(10):23143-64. PubMed ID: 26404236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances of epigenetic editing.
    Gjaltema RAF; Rots MG
    Curr Opin Chem Biol; 2020 Aug; 57():75-81. PubMed ID: 32619853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.